The first half of 2026 gave us a lot to track, and when I sat down to write this recap, I expected a collection of loosely connected developments. Mostly, that's what the half was. But one thread kept resurfacing across our coverage - in funding rounds, in acquisitions, in how the biggest companies structured their businesses - and it's worth naming before anything else: The buyer of (and to a certain extend also the investor in) women's health is changing.
Below is our recap, the numbers around it, and what we'll be watching in the second half.
The Buyer Is Changing
Call it an observation from our own coverage rather than a measured trend, but it connects more of the half than anything else. Several of the most notable rounds came from strategic and institutional sources rather than traditional VC: Securian Canada, an insurer, backing June Health. National payers co-leading maternal health rounds. The European Innovation Council and the UK's NIHR funding deep-tech diagnostics. And in the clearest signal of the half, the insurer WPS didn't invest in women's health - it acquired it, buying the maternal mental health platform Mavida outright.
The two largest disclosed rounds of the half point the same direction. Midi Health's $100 million Series D and Nourish's $100 million Series C were both built on insurance-covered models - Midi reaching 45 million covered women, Nourish available to over 200 million covered lives, typically at no cost to patients.
Taken together, the pattern reads like this: Payers and strategics are moving from reimbursing women's health toward funding it, and occasionally toward owning it. Whether that's a durable shift or a handful of coincident deals is one of the big questions we'll be tracking in H2.
The Funding Picture
The clearest read on the market these days comes from SVB's 2026 Women's Health report, which put roughly $2 billion of VC into women's health across the US and Europe in 2025 - a dip from the 2024 peak, but with a rebound projected for 2026 in both deal volume and total funding. SVB's own read is that the 2025 softness reflected discipline rather than weakness: Because women's health skews toward therapeutics and care delivery, it largely avoided the 2024 generalist AI hype that inflated (and then deflated) other verticals. Worth noting that this is SVB's framing, so take it with the appropriate grain of salt - but the underlying data on the rebound is there to see.
Dealroom's data (directional rather than precise) measures something different and worth knowing alongside it: Not absolute dollars, but women's health's share of total health VC, which has drifted down over the past decade even as absolute numbers grew. Both can be true at once - the sector is bigger than it was, and it still commands a smaller slice of health funding than it did a decade ago. If the payer shift above is real, it may partly explain how the sector keeps growing while its share of traditional health VC shrinks: Some of the capital simply isn't coming from VC anymore, and is often not picked up in reports.
The Definition Kept Broadening
One kind of growth this half was in scope - the range of conditions considered part of women's health. SVB's report (Yes, I really enjoyed digging into this one...) makes the point: The sector has expanded well beyond reproductive health to the full spectrum of women's health needs. Our coverage showed this as well. In May for example, pelvic health had a standout week, with UroMems ($60M), BlueWind ($47.8M), and NinaMED ($13.75M) raising a combined $121 million for incontinence devices.
Bone health drew attention with Osteoboost's $8 million raise for its FDA-cleared wearable for postmenopausal women. Metabolic health saw significant capital, from Nourish's $100 million to Signos ($20M) and Ilant Health ($15M).
Per Dealroom, menopause is now the fastest-heating sub-sector, with venture funding up 9% over 3 years to $104 million in 2025. The growth concentrated in areas a narrower definition would have excluded entirely.
The Category Matured
The other kind of growth was structural - not new conditions, but better-organized ways of delivering care. Single-point solutions kept giving way to integrated, life-stage platforms.
Maven relaunched a direct-to-consumer platform, Sword expanded Bloom into a full life-stage offering, Kindbody added pregnancy, menopause, and men's health programs, and whole-person models like Tia and June Health pushed to integrate primary care, gynecology, mental health, and hormonal care under one roof.
Mental health crossed from standalone niche to expected layer, arriving inside broader platforms through acquisition - the WPS/Mavida deal mentioned above, and Aeroflow buying Canopie in the same month to fold maternal mental health into its supplies-and-services platform. Consolidation showed up elsewhere too, including the April Reprotech and TMRW combination to create the largest tech-enabled fertility cryostorage company or ONTO acquiring Levy Health in the fertility space. .
AI Commanded a Real Premium
If the sector broadly avoided the generalist AI frenzy, AI still carried real weight within it - just attached to clinical value rather than hype.
One of the most concrete findings in SVB's report is that AI-enabled women's health companies command a median pre-money valuation of around $35 million - nearly triple their non-AI peers, a sharp break from prior years. And the premium isn't going to AI drug discovery or back-office automation; SVB notes it's concentrated in clinical tools that predict and prevent costly health events.
The honest caveat: A median valuation gap this large invites the question of whether it's a true re-rating or a selection effect - AI-enabled companies clustering at later stages, or the label attaching itself to anything with a model inside. SVB's data doesn't settle that, and neither can we. What would settle it is time: If the premium is real, it should survive the next 12 months of repricing and show up in the outcomes these tools are priced on - prevented events, payer contracts, renewals - not just in the next round's term sheet.
The deal flow at least matched the thesis. Xella Health launched with an AI platform screening for 130+ conditions, Ovum raised $4 million to build an AI-powered longitudinal health dataset, and earlier in the half, ONTO Health raised $20 million for AI-enabled fertility and longevity care. If the valuation gap holds, it suggests the market is pricing AI's value in women's health around prediction and prevention of expensive events - not consumer-facing features.
Diagnostics and Data Kept Advancing
Separate from the AI valuation story, the technical frontier of measurement moved fast. The race toward continuous hormone monitoring accelerated, with companies pursuing both direct measurement (Level Zero's biosensors, Impli's implantable patch, which won a £1.4M NIHR grant in June) and AI inference (Clair). SPRIND's €40 million Hormone Challenge, which we covered in depth, added the infrastructure layer by funding the shared reference dataset the field depends on.
Alongside continuous monitoring, at-home hormone testing proliferated and multi-condition screening platforms emerged. The through-line is a shift from occasional snapshots toward continuous, clinical-grade data - the raw material better women's health decisions depend on.
The Access Gap - and the Payer Answer
For all the expansion, the Cleveland Clinic's State of Women's Health report was a reminder of that there still is a lot of work to do: 45% of women say their biggest health concern is affording care - more than cancer, heart disease, or Alzheimer's. The scope of what women's health covers is widening faster than access to it.
Read against the rest of this recap, though, the finding lands differently than it first appears. The insurance-covered models behind the half's biggest rounds, and the payers investing in and acquiring women's health companies outright, are the market's working answer to exactly this problem: If women can't pay out of pocket, build the business on the entity that can.
The unresolved question is whether payer capture actually closes the access gap or merely decides who's inside it - because coverage-built models reach the women with the right employer or the right insurance card, and the 45% includes many women with neither. That tension, more than any single deal, is what I'd want founders and investors in this space to sit with.
What We're Watching in H2
A few open questions will shape the back half. First and above all, whether the payer shift is durable, whether payers co-leading rounds turn out to be the front edge of a pattern or a coincidence of timing. Whether the funding rebound SVB projects actually materializes. Whether the AI valuation premium survives repricing, or proves a temporary re-rating. And whether continuous monitoring companies can move from validation towards commercialization.
None of these has an obvious answer yet. What we can say though: The sector visibly broadened in scope, grew more structured, and - if our read is right - began changing who it answers to. Whether that adds up to durable maturation, or a category still finding its footing, is what the next 6 months should help us understand.
